Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 179


Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network.

Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Review.


Risk of drug-induced liver injury from tumor necrosis factor antagonists.

Björnsson ES, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, Gudbjörnsson B, Olafsson S.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):602-8. doi: 10.1016/j.cgh.2014.07.062. Epub 2014 Aug 15.


Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.


Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA.

Medicine (Baltimore). 2007 Jul;86(4):242-51.


Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.

Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM.

J Cutan Pathol. 2012 May;39(5):481-92. doi: 10.1111/j.1600-0560.2012.01894.x.


Drug-induced liver injury.

Leise MD, Poterucha JJ, Talwalkar JA.

Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016. Review.


Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.

Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, Houvenagel E, Berthelot JM, Pagnoux C, Dernis E, Melac-Ducamp S, Bouvard B, Asquier C, Martin A, Puechal X, Mariette X; Club Rhumatismes et Inflammation Section of the SFR.

Rheumatology (Oxford). 2013 May;52(5):868-74. doi: 10.1093/rheumatology/kes375. Epub 2013 Jan 3.


Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.


Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.

Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM.

Rheumatology (Oxford). 2006 Sep;45(9):1121-4. Epub 2006 Mar 1.


Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.

Chastek B, Fox KM, Watson C, Gandra SR.

Adv Ther. 2012 Aug;29(8):691-7. doi: 10.1007/s12325-012-0039-3. Epub 2012 Aug 16.


Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

Arthritis Rheum. 2009 May 15;61(5):560-8. doi: 10.1002/art.24463.


TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.

Williams VL, Cohen PR.

Int J Dermatol. 2011 May;50(5):619-25. doi: 10.1111/j.1365-4632.2011.04871.x. Review.


Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M.

Dig Dis Sci. 2013 Jun;58(6):1766-75. doi: 10.1007/s10620-012-2553-1. Epub 2013 Feb 2.


Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.

Béné J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P, Péré P, Gautier S.

Rheumatology (Oxford). 2014 Aug;53(8):1465-9. doi: 10.1093/rheumatology/keu145. Epub 2014 Mar 27.


[Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy - presentation of cases and review of literature].

Rösner S, Schad A, Kittner J, Rahman F, Wörns MA, Schuchmann M, Galle PR, Schattenberg JM.

Z Gastroenterol. 2014 Jan;52(1):58-63. doi: 10.1055/s-0033-1356224. Epub 2014 Jan 13. Review. German.


Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.

Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.


Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.

Serac G, Tubach F, Mariette X, Salmon-Céron D, Ravaud P, Lioté F, Laharie D, Ziza JM, Marguerie L, Bonnet C, Falgarone G, Nicolas N, Lortholary O, Chosidow O.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):726-9. doi: 10.1038/jid.2011.383. Epub 2011 Nov 24. No abstract available.


Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

Costa MF, Said NR, Zimmermann B.

Semin Arthritis Rheum. 2008 Jun;37(6):381-7. Epub 2007 Oct 30. Review.


T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.


Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.

Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M.

Semin Arthritis Rheum. 2011 Oct;41(2):256-64. doi: 10.1016/j.semarthrit.2010.11.002. Epub 2011 Feb 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk